Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Synvisc · 4 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Synvisc | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Synvisc (hylan G-F 20) | DEVICE | - |
| Synvisc | DEVICE | intra-articular, 3 weekly injections |
Inclusion Criteria: * Patients with symptomatic OA pain of shoulder (gleno-humeral) Exclusion Criteria: * Patients with current or prior conditions or treatment that would impede measurement of efficacy or safety
Synvisc is used for osteoarthritis, including osteoarthritis of the hip and symptomatic shoulder and ankle osteoarthritis. It is a viscosupplementation product developed by Sanofi for the treatment of osteoarthritis in various joints.
Synvisc is a viscosupplement that targets the joint space in osteoarthritis. It is designed to supplement the synovial fluid in joints affected by osteoarthritis, providing lubrication and cushioning to reduce pain and improve joint function.
Synvisc is developed by Sanofi, a multinational pharmaceutical company. Sanofi is publicly traded under the ticker symbol SNY on the NASDAQ stock exchange.
Synvisc is in Phase 3 clinical development for osteoarthritis. It has completed three Phase 3 trials in shoulder, hip, and ankle osteoarthritis, and it is not FDA approved based on the available data.
Synvisc has completed three Phase 3 trials: NCT00131300 for shoulder osteoarthritis, NCT00131326 for hip osteoarthritis, and NCT00131768 for ankle osteoarthritis. All trials are completed, with no active trials currently.
Synvisc is a brand name for hylan G-F 20, a derivative of hyaluronan. It is used for osteoarthritis treatment and is developed by Sanofi.